John Strang

February 12, 2024

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study

Abstract Background: The effects of cannabis are thought to be mediated by interactions between its constituents and the endocannabinoid system.…

October 11, 2023

Cannabidiol does not attenuate acute delta‐9‐tetrahydrocannabinol‐induced attentional bias in healthy volunteers: A randomised, double‐blind, cross‐over study

Abstract Aims: To test how attentional bias and explicit liking are influenced by delta‐9‐tetrahydrocannabinol (THC) and whether these effects are…

November 16, 2022

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios

Abstract As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful…

September 9, 2020

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products

Abstract Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and…

August 15, 2019

Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial

Abstract Background: Cannabis is the most commonly used illicit substance amongst people with psychosis. Continued cannabis use following the onset…

October 22, 2016

A randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention compared to treatment as usual for reduction of cannabis use and of relapse in early psychosis (CIRCLE): a study protocol for a randomised controlled trial

Abstract Background: Around 35–45 % of people in contact with services for a first episode of psychosis are using cannabis.…